Fig. 5 | Scientific Reports

Fig. 5

From: In-silico analysis unveiling the role of cancer stem cells in immunotherapy resistance of immune checkpoint-high pancreatic adenocarcinoma

Fig. 5

Association of driver mutations with stemness markers in PAAD. Plots depicting log fold change expression for stemness markers, (A) CD44, MET and POU5F1(OCT4) in case of wild-type KRAS or mutated KRAS groups; (B) MET and POU5F1 in case of wild-type CDKN2A or mutated CDKN2A groups; and, (C) CD44, MET and POU5F1 in case of wild-type TP53 and mutated TP53 groups. (D) Log fold change expression for stemness genes in wild-type and mutated SMAD4 groups is shown by heatmap. (A), (B), (C) and (D) are taken for PAAD (n = 170) from TIMER 2.0 database and Wilcoxon text was conducted to determine p value. (E) Kaplan Meier plot from kmplot.com showing overall survival probability in pancreatic cancer patients depending on low or high expression of CD44, MET and POU5F1 in them. (F) Heatmap spearman correlation depicting EPIC CAF infiltration scores with CSC genes as well as, CIBERSORT (ABS) Treg and M2 infiltration scores with CSC genes in PAAD (n = 179) using TIMER2.0. PAAD: Pancreatic adenocarcinoma, CAF: Cancer-associated fibroblast.

Back to article page